BSX - BSX ボストン・サイエンティフィック （）

MARLBOROUGH, Mass., Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at…

The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Thrombolysis Treatment Device industry. This wide-ranging market research report acts as a backbone for the success of

Tuesday’s additional top analyst upgrades and downgrades were on BJ’s Wholesale Club, Boston Scientific, Conagra Brands, NetApp, Norfolk Southern, Spirit Airlines, Stitch Fix, Target, Union Pacific and more.

https://www.investing.com/news/pro/citi-resumes-boston-scientific-at-buy-432SI-2967275

Boston Scientific Corporation with ticker code (BSX) now have 25 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 54 and 45 with a mean TP of 49.32. With the stocks previous close at 46.32 this now indicates there is a potential upside of 6.5%. The day 50 moving average is 43.01 and the 200 moving average now moves to 41.35. The market capitalisation for the company is $65,614m. Find out more information at: https://www.bostonscientific.com [stock_market_widget type="chart" template="basic" color="green" assets="BSX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $69,864m based on the market concensus. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

The global "Electro-Diagnostic Devices Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Electro-Diagnostic Devices market report highlight the latest development

The trading price of Boston Scientific Corporation (NYSE:BSX) floating higher at last check on Monday, October 03, closing at $39.88, 2.97% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $38.70 and $39.99. The company’s P/E ratio in the trailing 12-month period … Boston Scientific Corporation (NYSE: BSX) Stock Forecast: Potential To Pass $53.00 Within A Year Read More »

NORTHAMPTON, MA / ACCESSWIRE / October 3, 2022 / Truveta announced a strategic collaborative agreement with Boston Scientific Corporation whereby Boston Scientific researchers will be able to access data from Truveta that contains deidentified medical records from more than 65 million patients in the United States. According to Truveta, the collaboration seeks to improve long-term patient care and gain insights into health care disparities. Continue reading here. View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com. Contact Info: Spokesperson: Boston Scientific Website: https://www.bostonscientific.com/en-US/Home.html Email: info@3blmedia.com SOURCE: Boston Scientific

MARLBOROUGH, Mass., Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October 26, 2022 at 8:00 a.m. EDT. The call will be…

Boston Scientific (BSX) has entered into a collaboration with Truveta, which provides de-identified health data, to analyze patient outcomes related to use of the device companys products.

Thursday''s top analyst upgrades and downgrades included Abbott Laboratories, Azul, Boeing, Boston Scientific, Callon Petroleum, Corning, Datadog, Etsy, HCA Healthcare, Kohl''s, Medtronic, Merck, Netflix, Pioneer Natural Resources, Pure Storage, Qualcomm, Sabre and Sysco.

Boston Scientific''s (NYSE: BSX ) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short , which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

MARLBOROUGH, Mass., June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT. The call will be…

DUBLIN , June 22, 2022 /PRNewswire/ -- The "Global Neurology Devices Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global neurology devices market is expected to grow from $13.94 billion in 2021 to $15.91 billion in 2022 at a compound annual growth rate (CAGR) of 14.2%. The market is expected to grow to $25.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. Major companies in the neurology devices market include Medtronic Inc., Stryker Corporation, Terumo Corporation, Integra Lifesciences, Boston Scientific Corporation, Penumbra, Inc., B. Braun Group, Nevro, LivaNova, PLC, and Natus Medical. The neurology devices market consists of sales of neurology devices and related services by entities (organizations, sole traders, and partnerships) that produce neurology devices to diagnose and treat neurological diseases. The main types of neurology devices are cerebrospinal fluid management (CSF) devices and equipment, interventional neurology devices and equipment, neurosurgery devices and equipment, and neurostimulation devices.

Boston Scientific Corporation is shelling out $230 million in U.S. dollars to buy a Korean manufacturer called M.I.Tech Co., Ltd.